Dr. Oliver Freudenreich is an Associate Professor of Psychiatry at Harvard Medical School and a Psychiatrist at Massachusetts General Hospital (MGH). He serves as co-director of the MGH Schizophrenia Clinical and Research Program and directs the MGH Fellowship in Public and Community Psychiatry.
His academic interest is in the area of optimal psychopharmacological treatment for schizophrenia, including clozapine for refractory psychosis, early course schizophrenia, the role of medical morbidity in schizophrenia, the integration of medicine and psychiatry, and treatment adherence. In addition to his clinical and clinical trial expertise in schizophrenia, Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness or diagnostically difficult cases with psychosis. He is a deputy editor for the journal Psychosomatics. He has published extensively in his areas of interest and he wrote a handbook on psychotic disorders. Dr. Freudenreich is an active teacher who lectures regularly at national meetings and at his home institution. At MGH, he is the course director for the Department of Psychiatry’s monthly Morbidity and Mortality conference.